Streetbeat News

Products Services

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo provides daily trading strategies for SPY, QQQ, AAPL, MSFT, TSLA, NVDA, GOOGL, and META, based on a proprietary formula considering price, volume, and options flow. The memo outlines potential bullish and bearish price targets for each asset and advises traders to stay alert to market conditions. The session may be influenced by PMI data and triple witching, which could increase volatility. The memo is part of a service by RIPS, offering insights and real-time mentorship to Market Clubhouse members.

Portfolio Pulse from RIPS

December 15, 2023 | 3:19 pm

CBIH

Cannabis Bioscience International Holdings (OTC: CBIH) has had its registration statement for the public offering of over 10 billion shares declared effective by the SEC. The company plans to use the proceeds to fund cannabis clinical trials using AI. Texas, where CBIH is based, maintains strict cannabis laws, but some cities are moving towards decriminalization. The article also promotes Benzinga PotProfits, highlighting recent gains in cannabis stocks and teasing upcoming stock picks.

Portfolio Pulse from Jelena Martinovic

December 15, 2023 | 3:09 pm

ATOMUSD

ETHUSD

SOLUSD

TIAUSD

Cyber Fund has launched a $100 million venture capital division to accelerate projects combining blockchain technology and AI. The firm has previously invested in over 150 projects, including Ethereum, Dfinity, Cosmos, Solana, and Celestia. Cyber Fund has also developed products like P2P.org and Lido DAO, and through the =nil; Foundation, it has advanced cryptographic research. The new fund will focus on sectors such as advanced cryptography, DeFi, network states, cybernetic organizations, reputation systems, and AI-driven systems.

Portfolio Pulse from Murtuza Merchant

December 15, 2023 | 3:04 pm

STGW

Elspeth Rollert has been promoted to CEO of Stagwell Marketing Cloud (SMC), a proprietary suite of SaaS products by Stagwell (NASDAQ:STGW). She will lead the strategic direction and performance of SMC. Rollert has a background with Uber and Microsoft, and has been instrumental in SMC's growth through product development, acquisitions, and partnerships, including with Google Cloud. Stagwell reported a 7% revenue increase and 20% net revenue increase for SMC in Q3 2023. Rollert will be present at CES 2024.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 2:52 pm

AADI

Aadi Bioscience Inc (NASDAQ:AADI) stock fell after interim results from its PRECISION1 trial of nab-sirolimus showed a 26% ORR for TSC1 alterations and 11% ORR for TSC2 alterations. The trial, with no new safety concerns, will complete by end of 2024, with results expected in early 2025. AADI shares dropped 56.24% to $2.35 in premarket trading.

Portfolio Pulse from Vandana Singh

December 15, 2023 | 2:15 pm

BIIB

Biogen Inc. has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for SKYCLARYS, a treatment for Friedreich's Ataxia. This is a significant step towards potential approval and commercialization in the European market.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 2:07 pm

SCLX

Scilex Holding Company (NASDAQ:SCLX) has announced that a major national pharmacy chain will stock ELYXYB, a non-opioid pain management product for acute migraine treatment, in most of their stores across the U.S. This follows a previous initiative with another leading pharmacy chain and ongoing negotiations with additional chains. ELYXYB is FDA-approved and offers fast, long-lasting relief, addressing unmet needs for patients with insufficient response to triptan therapy or contraindications to its use.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 2:01 pm

AADI

Aadi Bioscience's stock price has declined following the release of interim results from the PRECISION1 trial of their drug nab-sirolimus.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 2:01 pm

MRK

NVS

The FDA has approved Merck & Co Inc's (NYSE:MRK) drug Welireg (belzutifan) for advanced renal cell carcinoma (RCC) in patients previously treated with PD-1/PD-L1 inhibitors and VEGF-TKI. This marks the first new treatment class approved for advanced RCC since 2015. The approval is based on the LITESPARK-005 trial results, where Welireg showed superior progression-free survival (PFS) and objective response rate (ORR) compared to Novartis AG's (NYSE:NVS) Afinitor (everolimus). MRK shares rose 0.58% in premarket trading.

Portfolio Pulse from Vandana Singh

December 15, 2023 | 1:59 pm

FSR

SGRY

VRCA

Verrica Pharmaceuticals' partner Torii Pharmaceutical announced positive Phase 3 trial results for TO-208 in Japan, boosting VRCA shares by 52%. Fisker released the final 2023 over-the-air software update for the Fisker Ocean, with plans for regular updates in 2024, increasing FSR shares by 11%. Surgery Partners' stock fell by 6% after announcing a proposed secondary offering of common stock.

Portfolio Pulse from ryanfaloona@benzinga.com

December 15, 2023 | 1:47 pm